s

Access Bio-Rad custom antibody generation services through the Scientist.com and ScienceExchange marketplaces.
s
A personal, no obligation quotation for a custom monoclonal antibody generation project
s

Our custom antibody services based in Neuried (Munich), Germany, are My Green Lab certified!
s
Tel: +49 (0) 89 80 90 95 45
Fax: +49 (0) 89 80 90 95 50
Office: Bio-Rad AbD Serotec GmbH, Campus Neuried, Anna-Sigmund-Str. 5, 82061 Neuried, Germany
Resources supporting the use of HuCAL® recombinant monoclonal antibodies
Discover the technology behind Bio-Rad’s custom recombinant antibodies.
Watch our latest video to see inside Bio-Rad’s custom antibody facility.
Learn from antibody experts how your requirements for specialized custom antibodies can become a reality through the use of HuCAL technology.

A High-Throughput Workflow for Determining Antibody-Antigen Binding Affinities Using Kinetic Titration

How specialized antibody reagents address the challenges of CAR-T cell therapy development
Dr Christian Frisch explains how we generate anti-idiotypic antibodies for bioanalytical assay development using the HuCAL recombinant antibody technology; recorded at the EBF 8th Open Meeting.
Hear how Bio-Rad’s recombinant anti-idiotypic antibodies, made using HuCAL technology, fulfill the high quality standards demanded for use in assays to support the clinical evaluation of monoclonal antibody drugs; recorded at the EBF 9th Open Meeting.
Michael Schwenkert describes how high sensitivity PK assays can be developed using specialized drug-target complex specific antibodies, avoiding the ELISA bridging format; recorded at the EBF 10th Open Meeting (Barcelona, November 2017).
Michael Schwenkert talks about challenges associated with the development of CAR-T cell therapies that can be addressed using anti-idiotypic antibodies, and explains how Bio-Rad generates custom antibodies for this application (Barcelona, November 2018).
Ulrich Mayer describes how bioanalytical scientists can address the challenges of robust, selective and sensitive PK and ADA assay development through the use of customized anti-biotherapeutic antibodies generated by Bio-Rad (Barcelona, November 2019).